Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60155 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2USP2CYP3A4MEN1MAPT | |
| SCHEMBL4940662 | 0.94 | USP2 (0.35) | SMN1; SMN2USP2CYP3A4MEN1MAPT | |
| SCHEMBL60752 | 0.84 | — | — | |
| SCHEMBL1470569 | 0.78 | TSHR (0.50) | SMN1; SMN2MEN1MAPTKMT2ALMNA | |
| SCHEMBL2873944 | 0.78 | TSHR (0.50) | SMN1; SMN2MEN1MAPTKMT2ALMNA | |
| SCHEMBL67396 | 0.78 | TSHR (0.50) | SMN1; SMN2MEN1MAPTKMT2ALMNA | |
| SCHEMBL12500356 | 0.78 | TSHR (0.50) | SMN1; SMN2MEN1MAPTKMT2ALMNA | |
| SCHEMBL730035 | 0.78 | TSHR (0.50) | SMN1; SMN2MEN1MAPTKMT2ALMNA | |
| SCHEMBL1470503 | 0.78 | TSHR (0.50) | SMN1; SMN2MEN1MAPTKMT2ALMNA | |
| SCHEMBL56398 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | PROVID PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4112053-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308585-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | Provid Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023018155-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-02-16 | — | — | WO | disclosed |
| EP-4112053-A1 | TREATMENT OF SYNUCLEINOPATHIES | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3525788-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2022-05-25 | — | — | EP | disclosed |
| WO-2004009610-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003105774-A2 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | HLA-DRB1, HLA-B, HLA-C | SMN1; SMN2 2759/4885USP2 1570/4885CYP3A4 1810/4885 |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | SMN1; SMN2 3108/4885USP2 1990/4885CYP3A4 3564/4885 |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | CASP5, NLRP3, LITAF | SMN1; SMN2 3942/4885USP2 2022/4885CYP3A4 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.